SPYH:XETRA:XETRA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 201.35

Change

+1.39 (+0.70)%

Market Cap

N/A

Volume

1.00K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-09 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JARI:XETRA Amundi Index Solutions - Amund..

-0.11 (-0.24%)

USD 100.65B
EUNL:XETRA iShares Core MSCI World UCITS ..

-0.05 (-0.05%)

USD 84.07B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.01 (+0.04%)

USD 79.79B
AW15:XETRA UBS (Irl) ETF plc - MSCI Japan..

-0.06 (-0.47%)

USD 58.88B
FJPR:XETRA Fidelity Sustainable Research ..

-0.03 (-0.60%)

USD 44.90B
EXX7:XETRA iShares Nikkei 225 UCITS ETF (..

+0.02 (+0.09%)

USD 28.25B
SPYL:XETRA SPDR S&P 500 UCITS ETF USD Acc..

-0.04 (-0.30%)

USD 23.49B
PPFB:XETRA iShares Physical Gold ETC EUR

+0.02 (+0.03%)

USD 20.66B
XDEE:XETRA Xtrackers S&P 500 Equal Weight..

-0.04 (-0.43%)

USD 12.74B
EUN5:XETRA iShares Core Corporate Bond UC..

-0.03 (-0.02%)

USD 12.26B

ETFs Containing SPYH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.75% 41% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.75% 44% F 42% F
Trailing 12 Months  
Capital Gain -10.03% 11% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.03% 13% F 19% F
Trailing 5 Years  
Capital Gain 22.73% 38% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.73% 39% F 40% F
Average Annual (5 Year Horizon)  
Capital Gain 9.13% 62% D 62% D
Dividend Return 9.13% 61% D- 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.25% 69% C- 76% C+
Risk Adjusted Return 110.66% 94% A 95% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike